CJC-1295 + Ipamorelin 30mg — Vial Spec, Reconstitution Math & COA

CJC-1295 + Ipamorelin 30mg Vial Specifications & Lab Availability

In preclinical laboratory settings, high-mass co-lyophilized preparations offer reduced container-closure handling and improved standardization across extended experimental series. A 30mg combination vial contains 30 total milligrams of active peptide mass, generally divided evenly as 15mg of the growth hormone-releasing hormone (GHRH) analog CJC-1295 (without Drug Affinity Complex) and 15mg of the selective growth hormone secretagogue receptor (GHSR) agonist Ipamorelin. This exact mass ratio is designed to saturate both distinct receptor pathways simultaneously in cellular and animal models.

It is important to note current catalog availability: PX1 Research supplies high-purity, batch-tested research peptides manufactured under strict USA production standards. While specialized 30mg combination vials are custom-synthesized for bulk research contracts and institutional inquiries, our standard stock catalog features the high-demand CJC-1295 No DAC + Ipamorelin 10mg Blend. Investigators conducting routine assay screening or lower-volume preclinical trials can review our full range of single compounds and blends via our all peptides catalog.

Dual Receptor Mechanism: Co-Activation of GHRH-R and GHSR-1a

The primary scientific rationale for combining CJC-1295 and Ipamorelin in a single matrix lies in their complementary molecular targets within the somatotropic axis. CJC-1295 is a synthetic 29-amino-acid peptide modification of the endogenous GHRH sequence (1-29). By substituting positions at Ala2, Gln8, Ala15, and Leu27, CJC-1295 demonstrates enhanced enzymatic stability against dipeptidyl peptidase-4 (DPP-IV) cleavage while retaining high binding affinity for the growth hormone-releasing hormone receptor (GHRH-R) on pituitary somatotropes. Preclinical studies suggest that GHRH-R activation triggers adenylate cyclase, elevating intracellular cyclic AMP (cAMP) and driving gene transcription for growth hormone synthesis and release.

Conversely, Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that functions as a highly selective agonist at the growth hormone secretagogue receptor (GHSR-1a), also known as the ghrelin receptor. Activation of GHSR-1a triggers a phospholipid-dependent signaling cascade through protein kinase C (PKC) and intracellular calcium mobilization. When introduced concurrently in vitro or in rodent models, the cAMP-dependent pathway (CJC-1295) and the calcium-dependent pathway (Ipamorelin) act synergistically. This dual-signal mechanism induces a amplificated pulse of growth hormone secretion without causing significant elevations in baseline cortisol, adrenocorticotropic hormone (ACTH), or prolactin levels.

Preclinical Research Applications in Somatotropic Signaling

In vivo animal models and in vitro tissue preparations utilize CJC-1295 + Ipamorelin combinations to evaluate downstream physiological parameters linked to elevated growth hormone (GH) and insulin-like growth factor 1 (IGF-1) expression. Studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research, CJC-1295 provides a durable baseline stimulus that prevents rapid receptor desensitization when properly modulated.

Key preclinical research areas involving this dual-peptide combination include:

1. Nitrogen Retention & Skeletal Muscle Metabolism: Rodent models receiving co-administrations of GHRH analogs and GHRPs display enhanced amino acid uptake, upregulated mammalian target of rapamycin (mTOR) signaling, and increased protein synthesis in skeletal muscle tissue.

2. Collagen Biosynthesis & Tissue Repair: In vitro assays utilizing fibroblast and tenocyte cultures demonstrate accelerated extracellular matrix remodeling, driven by IGF-1 signaling downstream of somatotrope activation.

3. Adipose Tissue Oxidation: Preclinical observations indicate that elevated systemic GH promotes lipolysis in visceral and subcutaneous adipocyte cultures via hormone-sensitive lipase (HSL) activation.

4. Bone Mineral Density & Cellular turnover: Long-term animal trials measure osteoblast proliferation and trabecular microarchitecture reinforcement under sustained somatotropic tone.

Reconstitution Mathematics & Volumetric Calculations (30mg Vial)

Accurate reconstitution is critical when handling a 30mg mass vial to ensure precise microgram delivery per volumetric aliquot. Because the vial contains a dense cake of co-lyophilized material (30,000 micrograms total peptide mass), laboratories must select a diluent volume that balances volumetric accuracy with peptide solubility. Bacteriostatic water (0.9% benzyl alcohol preserved) is the standard diluent for bench top research stability.

Below are the specific concentration metrics based on diluent addition to a 30mg combined vial (assuming a standard 15mg CJC-1295 / 15mg Ipamorelin matrix):

• Reconstitution with 1.0 mL Diluent: Total Peptide Concentration: 30.0 mg/mL (30.0 µg/µL) Individual Yield per 10 µL (0.01 mL): 150 µg CJC-1295 + 150 µg Ipamorelin (300 µg total blend).

• Reconstitution with 2.0 mL Diluent: Total Peptide Concentration: 15.0 mg/mL (15.0 µg/µL) Individual Yield per 10 µL (0.01 mL): 75 µg CJC-1295 + 75 µg Ipamorelin (150 µg total blend).

• Reconstitution with 3.0 mL Diluent: Total Peptide Concentration: 10.0 mg/mL (10.0 µg/µL) Individual Yield per 10 µL (0.01 mL): 50 µg CJC-1295 + 50 µg Ipamorelin (100 µg total blend).

To quickly verify custom dilution ratios, stock concentrations, or unit-to-volume conversions, researchers should utilize our interactive laboratory reconstitution calculator.

High-Volume Aliquoting & Storage Protocols

Because a 30mg vial represents a significant quantity of active reagent, proper storage and handling after initial reconstitution are essential to preserve peptide integrity over extended experimental durations. Lyophilized cake stored in a controlled environment at -20°C is stable for extended periods; however, once solubilized, peptides are vulnerable to hydrolysis, oxidation, and surface adsorption.

To maintain maximal biological activity after adding bacteriostatic water, observe the following laboratory protocols:

1. Avoid Vigorous Agitation: Gently swirl the glass vial until the lyophilized cake fully dissolves into a clear solution. Never vortex or shake violently, as shear forces can denature delicate peptide tertiary structures.

2. Sub-Aliquot Working Volumes: If the reconstituted solution will not be fully consumed within 5 to 7 days, pipette the liquid into sterile, low-binding microcentrifuge tubes in single-use working volumes.

3. Thermal Control: Store reconstituted aliquots at 2°C to 8°C for short-term assays (up to 28 days with benzyl alcohol diluent). For longer storage, freeze aliquots at -80°C to eliminate enzymatic degrade, avoiding repeated freeze-thaw cycles.

4. Light Protection: Keep reconstitutions in dark storage boxes or amber microcentrifuge tubes to prevent photo-oxidation of vulnerable amino acid residues such as tryptophan (in Ipamorelin) or histidine.

Analytical Verification: Lot-Matched COA, HPLC & Endotoxin Standards

Research validity depends entirely on compound purity, identity, and freedom from biological contamination. Every lot of peptide produced for PX1 Research undergoes stringent third-party testing at an independent, ISO 17025-accredited laboratory before release.

When purchasing high-density peptides, researchers receive access to a batch-specific Certificate of Analysis (COA) validating three key parameters:

• High-Performance Liquid Chromatography (HPLC): Confirms chemical purity. PX1 Research enforces a strict minimum purity threshold of ≥99.0% for all catalog compounds, ensuring that residual counter-ions or truncation sequences do not compromise assay data.

• Mass Spectrometry (MS): Confirms exact molecular mass against theoretical predictions. For CJC-1295 (without DAC, C152H252N44O42, theoretical MW 3357.9 g/mol) and Ipamorelin (C38H49N9O5, theoretical MW 711.86 g/mol), MS peaks verify correct molecular assembly.

• Bacterial Endotoxin Testing (LAL Assay): Essential for cell culture and animal safety. Products are tested via Limulus Amebocyte Lysate assay to confirm endotoxin levels fall well below target safety thresholds (<0.01 EU/µg).

Comparative Analysis: CJC-1295 / Ipamorelin vs. Alternative GHRH Analogs

When designing somatotropic research frameworks, investigators must evaluate how the CJC-1295 (No DAC) + Ipamorelin combination compares to alternative secretagogues and GHRH peptides within the same class. Selecting the appropriate molecular tool depends on required receptor specificity, half-life demands, and experimental end-points.

Consider the following comparative profiles across related research compounds:

• Sermorelin: Sermorelin is a truncated 29-amino-acid GHRH fragment (1-29) amide. Unlike CJC-1295 No DAC (which contains four strategic amino acid substitutions to resist DPP-IV degradation), Sermorelin exhibits a significantly shorter plasma half-life in preclinical models (~10–12 minutes versus ~30 minutes for CJC-1295).

• Tesamorelin: Tesamorelin is a stabilized GHRH analog featuring a trans-3-hexenoic acid group attached to the N-terminal tyrosine residue. Preclinical models show high potency for visceral fat oxidation assays, though it exhibits distinct kinetic properties compared to CJC-1295.

• GHRP-2: As a second-generation growth hormone-releasing peptide, GHRP-2 acts on GHSR-1a similarly to Ipamorelin. However, in vitro signaling data indicate that GHRP-2 causes minor collateral elevations in ACTH, cortisol, and prolactin levels, whereas Ipamorelin demonstrates complete selectivity for GH release without stimulating secondary endocrine axes.

For additional mechanistical breakdowns across secretagogue classes, explore our centralized scientific research hub.

Optimal Format Selection: 30mg vs. Standard 10mg Formulations

Determining whether to utilize a 30mg combination vial or smaller unit formulations (such as 5mg or 10mg blends) depends on the scale, setup, and duration of the experimental protocol.

1. High-Volume / Automated Platforms (30mg Rationale): Laboratories utilizing liquid-handling robots, high-throughput cellular screening platforms, or long-term multi-subject animal cohorts benefit from 30mg vials. Preparing a single concentrated stock minimizes batch-to-batch reconstitution variability and reduces total packaging waste.

2. Serial Single-Assay Benchwork (10mg Rationale): For smaller exploratory studies, individual bench assays, or protocols requiring fresh peptide reconstitution every few days, standard sizes such as the CJC-1295 No DAC + Ipamorelin 10mg Blend are preferable. Smaller vial sizes mitigate the risk of degradation caused by extended aqueous storage or multiple handling events.

Institutional laboratories requiring customized fill volumes, custom combination ratios, or bulk batch purchasing are encouraged to register through our wholesale lab account portal.

PX1 Research Quality Standard and Domestic Shipping Guarantee

At PX1 Research, we prioritize analytical precision, transparency, and reliable supply chain security for the scientific community. All peptides are synthesized in state-of-the-art, GMP-compliant facilities in the United States and subject to rigid quality assurance verification.

Key operational differentiators include:

• USA Synthesis & Manufacturing: Pure, highly stable lyophilizates manufactured under strictly controlled cleanroom conditions.

• ISO 17025 Third-Party Verification: Full HPLC/MS spectrum analysis and endotoxin testing per specific batch lot.

• Fast Domestic Fulfillment: Orders ship directly from our primary distribution hubs in California and Arizona with same-day shipping on orders placed Monday through Friday before cut-off times.

• Non-Degraded Temperature Assurance: Protective packaging engineered to insulate lyophilized peptides against thermal degradation during transit.